ADC Therapeutics SA (ADCT) Announces CEO Transition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to ADC Therapeutics SA (ADCT) Announces CEO Transition

ADC Therapeutics Announces CEO Transition

May 9, 2022 7:00 AM EDT

Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik

Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. Dr. Martin will serve... More